Nuvalent (NUVL) Accumulated Expenses (2020 - 2026)
Nuvalent (NUVL) reported Accumulated Expenses of $58.9 million for Q1 2026, up 20.56% on a YoY basis from $48.9 million in Q1 2025, and up 247.89% quarter-over-quarter from $16.9 million in Q4 2025.
Nuvalent (NUVL) Accumulated Expenses (2020 - 2026) Analysis & Trends
Nuvalent has reported Accumulated Expenses for 7 years, with the latest figure at $58.9 million in Q1 2026.
- For the quarter ending Q1 2026, Accumulated Expenses rose 20.56% year-over-year to $58.9 million; the trailing twelve-month figure through Mar 2026 stood at $58.9 million (up 20.56% YoY), and the FY2025 full-year result was $16.9 million, up 62.03% from the prior year.
- Accumulated Expenses for Q1 2026 stood at $58.9 million, up from $16.9 million in the prior quarter.
- The five-year high for Accumulated Expenses was $67.1 million in Q3 2025, with the low at $3.9 million in Q1 2022.
- Historically, Accumulated Expenses has averaged $23.0 million across 5 years, with a median of $16.9 million in 2025.
- Annual changes were most pronounced in 2022 — Accumulated Expenses soared 195.81% — and 2025, when it plunged 74.69%.
- Nuvalent's Accumulated Expenses stood at $12.3 million in 2022, then soared by 83.53% to $22.5 million in 2023, then tumbled by 53.65% to $10.5 million in 2024, then soared by 62.03% to $16.9 million in 2025, then surged by 247.89% to $58.9 million in 2026.
- The last three Accumulated Expenses figures came in at $58.9 million (Q1 2026), $16.9 million (Q4 2025), and $67.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Nuvalent | 9.70 Bn | 9.70 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 58.92 Mn |
| Dec 31, 2025 | 16.94 Mn |
| Sep 30, 2025 | 67.14 Mn |
| Jun 30, 2025 | 7.79 Mn |
| Mar 31, 2025 | 48.87 Mn |
| Dec 31, 2024 | 10.45 Mn |
| Sep 30, 2024 | 35.20 Mn |
| Jun 30, 2024 | 30.79 Mn |
| Mar 31, 2024 | 20.03 Mn |
| Dec 31, 2023 | 22.55 Mn |
| Sep 30, 2023 | 19.32 Mn |
| Jun 30, 2023 | 12.68 Mn |
| Mar 31, 2023 | 10.59 Mn |
| Dec 31, 2022 | 12.29 Mn |
| Sep 30, 2022 | 8.36 Mn |
| Jun 30, 2022 | 6.01 Mn |
| Mar 31, 2022 | 3.88 Mn |
| Dec 31, 2021 | 5.89 Mn |
| Sep 30, 2021 | 4.31 Mn |
| Jun 30, 2021 | 2.03 Mn |